FOXO4-DRI results: what to expect and when
An experimental cell-clearing peptide with mouse findings and no established human dose.
Also called: FOXO4 DRI, FOXO4-D-retro-inverso, FOX04-DRI, Proxofim.
Senolytic peptides · Experimental FOXO4-p53 interaction-disrupting peptide · Evidence: Animal studies only.
No human dosing study found. Studies of donated human cells or removed tissue are lab work, not human treatment studies.
Key studies
- First mouse and cell experiments: The peptide cleared some senescent cells and improved selected mouse health measures. (source)
- Testosterone in aged mice: Testosterone increased in aged mice; human fertility benefits remain untested. (source)
- Human cartilage cells in a dish: Fewer senescent cells did not translate into better cartilage formation. (source)
- Radiation and lung scarring in mice: Targeting altered fibroblasts improved radiation responses in mouse models. (source)
- Chemically induced lung scarring: Three doses reduced lung-scarring measures in this mouse model. (source)
- Pulmonary hypertension harm signal: FOXO4-DRI worsened lung-vessel function in one mouse model. (source)
Related to FOXO4-DRI
- MOTS-c: A peptide the body makes; injection benefits and safety remain unproven.
- Epitalon: A peptide with telomerase effects in cells, but no proof that people live longer.
- Humanin: A peptide the body makes; injection benefits and safety remain unproven.
- Thymalin: A calf thymus extract studied for immune problems, with uncertain safety and product identity.
- Gonadorelin: A short-acting fertility hormone used in tests and specialist pump therapy.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Anaphylaxis, NHS · NHS · 2023
- Using intramuscular injections in people on oral anticoagulants, NHS Specialist Pharmacy Service · NHS Specialist Pharmacy Service · 2023
- Access an unapproved therapeutic good (health practitioners), Therapeutic Goods Administration
- Pulmonary hypertension, NHS
- Supply unlicensed medicinal products (specials), MHRA · MHRA
- Unapproved Drugs, FDA
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.